Published Wed, 20 May 2020 12:32:08 -0400 on Seeking Alpha
XLV owns a portfolio of large-cap healthcare stocks in the U.S.
Many stocks in XLV’s portfolio have consistently increased their dividends in the past 10 years.
XLV is overvalued but it has a better growth profile than the S&P 500 Index.
The Health Care Select Sector SPDR ETF (XLV) owns a portfolio of large-cap healthcare stocks in the S&P 500 Index. The ETF is a nice defensive choice as demands for treatment and healthcare services do not diminish even in an economic recession. Many stocks in XLV’s portfolio have consistently increased their dividends in the past and should be able to continue to grow their dividends in the future. XLV should also benefit from an ageing population in the world. It also has a better growth profile than the S&P 500 Index. Although XLV is overvalued when compared to its historical average, we believe XLV is still a good investment choice for investors with a long-term investment horizon.
Data by YCharts
Stocks in XLV’s portfolio are recession-resilient stocks
The healthcare industry is a nice sector to invest due to its recession-resilient businesses because there will always be people that will need medical treatment and care regardless of an economic recession. These stocks will also benefit from an ageing population. According to a report by the United Nations, the number of people aged 60 years or older will double by 2050 from the current level today (see chart below). Therefore, we expect the need for drugs, medical equipment, and care to continue to grow rapidly in the next few decades.
Source: United Nations
Stocks in XLV’s portfolio have consistently increased their dividends every year
Stocks in XLV’s portfolio are dividend stocks. Since the healthcare industry is a recession-resilient industry, we think most of the companies’ dividends are safe in a recessionary environment today. Below is a chart that shows the dividend history of... Read more
|Stock name||Last trade||P/E||Earnings/Share||Dividend/Share||Dividend yield|
|JOHNSON & JOHNSON||130.43||21.6||6.03||3.80||2.93|
|MERCK & CO||83.31||23.3||3.57||2.20||2.69|
|THERMO FISHER SCIENTIFIC||294.97||33.6||8.77||0.76||0.26|
Older articles featuring Abbvie (ABBV):Build The Ultimate, 6.6%-Yielding, Sleep-Well-At-Night Retirement Portfolio With These 17 Blue-Chips
The Retiree's Dividend Portfolio - Jane's August Update: Preferred Exchange
50 Billionaire Holdings, 27 Pay Dividends, 2 To Buy In September
Dividend Aristocrats See 6 Star September Selections
Dividend Income Update: August 2020
When Tech Stocks Fail You, Choose These 5 Undervalued, Low-Risk Dividend Aristocrats
20 More Stocks I Hope To Buy During The Next Market Sell-Off (High Yield Edition)
A 91 Kiplinger 'Most Reliable Dividend Stocks On Earth' September Update
Nicholas Ward's Dividend Growth Portfolio: August 2020 Review
33 Dividend Stocks Fit For COVID-19 Times: A September Update